|
1
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P and Huang L:
Homoharringtonine induces apoptosis and inhibits STAT3 via
IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer
cells. Sci Rep. 5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X,
Yin T, Jiang L and Wang Y: Continuous exposure of non-small cell
lung cancer cells with wild-type EGFR to an inhibitor of EGFR
tyrosine kinase induces chemoresistance by activating STAT3. Int J
Oncol. 46:2083–2095. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sudo M, Mori S, Madan V, Yang H, Leong G
and Koeffler HP: Short-hairpin RNA library: Identification of
therapeutic partners for gefitinib-resistant non-small cell lung
cancer. Oncotarget. 6:814–824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahn SH, Jeong EH, Lee TG, Kim SY, Kim HR
and Kim CH: Gefitinib induces cytoplasmic translocation of the CDK
inhibitor p27 and its binding to a cleaved intermediate of caspase
8 in non-small cell lung cancer cells. Cell Oncol (Dordr).
37:377–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chao TT, Wang CY, Lai CC, Chen YL, Tsai
YT, Chen PT, Lin HI, Huang YC, Shiau CW, Yu CJ and Chen KF: TD-19,
an erlotinib derivative, induces epidermal growth factor receptor
wild-type nonsmall-cell lung cancer apoptosis through
CIP2A-mediated pathway. J Pharmacol Exp Ther. 351:352–358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bokobza SM, Jiang Y, Weber AM, Devery AM
and Ryan AJ: Combining AKT inhibition with chloroquine and
gefitinib prevents compensatory autophagy and induces cell death in
EGFR mutated NSCLC cells. Oncotarget. 5:4765–4778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang H, Zhao PJ, Su D, Feng J and Ma SL:
Paris saponin I induces apoptosis via increasing the Bax/Bcl-2
ratio and caspase-3 expression in gefitinib-resistant non-small
cell lung cancer in vitro and in vivo. Mol Med Rep. 9:2265–2272.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong FM, Zhao J, Wang J and Faivre-Finn C:
Radiation dose effect in locally advanced non-small cell lung
cancer. J Thorac Dis. 6:336–347. 2014.PubMed/NCBI
|
|
11
|
Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY,
Chen JJ, Chen HW and Yang PC: Curcumin induces EGFR degradation in
lung adenocarcinoma and modulates p38 activation in intestine: The
versatile adjuvant for gefitinib therapy. PLoS One. 6:e237562011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao W, Bao P, Qi H and You H: Resveratrol
down-regulates survivin and induces apoptosis in human
multidrug-resistant SPC-A-1/CDDP cells. Oncol Rep. 23:279–286.
2010.PubMed/NCBI
|
|
13
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li J, Viallet J and Haura EB: A small
molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis
and enhances cisplatin-induced apoptosis in non-small cell lung
cancer cells. Cancer Chemother Pharmacol. 61:525–534. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morgillo F, Kim WY, Kim ES, Ciardiello F,
Hong WK and Lee HY: Implication of the insulin-like growth
factor-IR pathway in the resistance of non-small cell lung cancer
cells to treatment with gefitinib. Clin Cancer Res. 13:2795–2803.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hotta K, Tabata M, Kiura K, Kozuki T,
Hisamoto A, Katayama H, Takigawa N, Fujimoto N, Fujiwara K, Ueoka H
and Tanimoto M: Gefitinib induces premature senescence in non-small
cell lung cancer cells with or without EGFR gene mutation. Oncol
Rep. 17:313–317. 2007.PubMed/NCBI
|
|
17
|
Fan XX, Li N, Wu JL, Zhou YL, He JX, Liu L
and Leung EL: Celastrol induces apoptosis in gefitinib-resistant
non-small cell lung cancer cells via caspases-dependent pathways
and Hsp90 client protein degradation. Molecules. 19:3508–3522.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li B, Ren S, Li X, Wang Y, Garfield D,
Zhou S, Chen X, Su C, Chen M, Kuang P, et al: MiR-21 overexpression
is associated with acquired resistance of EGFR-TKI in non-small
cell lung cancer. Lung Cancer. 83:146–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song JY, Kim CS, Lee JH, Jang SJ, Lee SW,
Hwang JJ, Lim C, Lee G, Seo J, Cho SY and Choi J: Dual inhibition
of MEK1/2 and EGFR synergistically induces caspase-3-dependent
apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM
upregulation. Invest New Drugs. 31:1458–1465. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ansari J, Palmer DH, Rea DW and Hussain
SA: Role of tyrosine kinase inhibitors in lung cancer. Anticancer
Agents Med Chem. 9:569–575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao
T, Peng P, Chen Y, Gui Q and Yu S: Knockdown of the Bcl-2 gene
increases sensitivity to EGFR tyrosine kinase inhibitors in the
H1975 lung cancer cell line harboring T790M mutation. Int J Oncol.
42:2094–2102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen G, Umelo IA, Lv S, Teugels E, Fostier
K, Kronenberger P, Dewaele A, Sadones J, Geers C and De Grève J:
miR-146a inhibits cell growth, cell migration and induces apoptosis
in non-small cell lung cancer cells. PLoS One. 8:e603172013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee YC, Lee LM, Yang CH, Lin AM, Huang YC,
Hsu CC, Chen MS, Chi CW, Yin PH, Kuo CD, et al: Norcantharidin
suppresses cell growth and migration with enhanced anticancer
activity of gefitinib and cisplatin in human non-small cell lung
cancer cells. Oncol Rep. 29:237–243. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang B, Jiao J, Liu Y, Guo LX, Zhou B, Li
GQ, Yao ZJ and Zhou GB: Gefitinib analogue V1801 induces apoptosis
of T790M EGFR-harboring lung cancer cells by up-regulation of the
BH-3 only protein Noxa. PLoS One. 7:e487482012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan XX, Yao XJ, Xu SW, Wong VK, He JX,
Ding J, Xue WW, Mujtaba T, Michelangeli F, Huang M, et al:
(Z)3,4,5,4′-trans-tetramethoxystilbene, a new analogue of
resveratrol, inhibits gefitinb-resistant non-small cell lung cancer
via selectively elevating intracellular calcium level. Sci Rep.
5:163482015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu T, Wang Z, Liu Y, Mei Z, Wang G, Liang
Z, Cui A, Hu X, Cui L, Yang Y and Liu CY: Interleukin 22 protects
colorectal cancer cells from chemotherapy by activating the STAT3
pathway and inducing autocrine expression of interleukin 8. Clin
Immunol. 154:116–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Imamura Y, Wang PL, Masuno K and Sogawa N:
Salivary protein histatin 3 regulates cell proliferation by
enhancing p27(Kip1) and heat shock cognate protein 70
ubiquitination. Biochem Biophys Res Commun. 470:269–274. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alam MM, Sohoni S, Kalainayakan SP,
Garrossian M and Zhang L: Cyclopamine tartrate, an inhibitor of
Hedgehog signaling, strongly interferes with mitochondrial function
and suppresses aerobic respiration in lung cancer cells. BMC
Cancer. 16:1502016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li LH, Wu P, Lee JY, Li PR, Hsieh WY, Ho
CC, Ho CL, Chen WJ, Wang CC, Yen MY, et al: Hinokitiol induces DNA
damage and autophagy followed by cell cycle arrest and senescence
in gefitinib-resistant lung adenocarcinoma cells. PLoS One.
9:e1042032014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Inamura K and Ishikawa Y: MicroRNA in lung
cancer: Novel biomarkers and potential tools for treatment. J Clin
Med. 5(pii): E362016. View Article : Google Scholar : PubMed/NCBI
|
